Loading data for FBIOP — first visit, this takes a few seconds.
Fortress Biotech, Inc. (FBIOP)
NasdaqCM: FBIOP
· 即時價格 · USD
18.75
+0.19 (1.02%)
收盤價： Sep 11, 2026, 2:24 PM
18.37
+0.27%
盤後: 4:10 PM
股價、關鍵數字和最新消息，都在這一頁。
Fortress Biotech, Inc.（FBIOP）股價、分析與資料
1.02% (1D)
| 買價 | 18.52 |
| 市值 | n/a |
| 營收 (ttm) | 68.5M |
| 淨利（ttm） | 103M |
| 1.19 | |
| -0.86 | |
| n/a | |
| n/a | |
| P/B (ttm) | 3.74 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 18.57 |
| 成交量 | 7,843 |
| 20 日平均成交量 | 13,438 |
| 開盤價 | 18.55 |
| 前收盤價 | 18.56 |
| 當日區間 | 18.54 - 18.80 |
| 52 週範圍 | 6.27 - 21.43 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | Jun 14, 2024 |
關於 FBIOP
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical ...
完整的公司簡介財報驚奇
Fortress Biotech 已於 Invalid Date 公布季度財報：
- 營收為 n/a 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 低於預期 , 年增 NaN% 成長.
第 1 頁，共 2 頁